Proton Beam Therapy for Abdominal Neuroblastoma
Official title: Pencil Beam Scanning Proton Beam Radiotherapy for the Management of Abdominal Neuroblastoma - An Evaluative Commissioning in Protons (ECIP) Study
Run by The Christie NHS Foundation Trust · NCT06804447 · Data updated 2026-11-12
This study tests Proton Beam Therapy for children with abdominal neuroblastoma to see if it can reduce side effects while treating the cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 3 Months and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | The Christie NHS Foundation Trust Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 2 sites (London and 1 other locations) |
| Status | Recruiting |
| Started | June 4, 2026 |
| Main results expected | May 1, 2030 |
| Study ends | May 1, 2030 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT06804447 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with histologically confirmed abdominal or abdominal-pelvic neuroblastoma who are fit for radical radiotherapy and whose guardians consent to treatment and data use.
✕Probably not a fit
Patients who are not candidates for radiotherapy or who have conditions contraindicating proton therapy may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program evaluates the use of Proton Beam Therapy (PBT) in pediatric abdominal neuroblastoma as part of Evaluative Commissioning in Protons (ECIP). Eligible patients are offered PBT at UK centres and may participate alongside other radiotherapy studies; the approach aims to limit radiation exposure to healthy tissues compared with standard photon therapy. The study is not randomized and focuses on real-world referral and treatment within NHS England, with data stored for research purposes. Patient safety, consent, and follow-up assessments are integral, including consideration of potential late effects and pregnancy considerations for those of childbearing potential. The Christie NHS Foundation Trust leads the effort with collaboration from University College London Hospitals.
Why it matters
Potential benefit: If successful, PBT could reduce radiation to healthy tissues, potentially lowering treatment-related side effects for children with abdominal neuroblastoma.
How similar studies have gone: Previous evidence from proton therapy efforts supports reductions in dose to healthy tissue, but this specific evaluative commissioning approach in abdominal neuroblastoma is not a randomized prior trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient with histologically confirmed abdominal or abdominal-pelvic neuroblastoma who are eligible and fit for radical radiotherapy. * Written informed consent from patient, parent or guardian - this includes consent for the minimum baseline, treatment and follow up assessments; and for their data to be stored and used for research, within the appropriate Proton Clinical Outcomes Units and NHS Proton Registry. * Patients registered female at birth of childbearing potential agree to use effective contraception between the planning Computed Tomography (CT) scan and the end of treatment. Exclusion Criteria: * Pregnant patient
Where it's running
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom Recruiting -
The Christie NHS Foundation Trust
Manchester, United Kingdom Recruiting
Study contacts
- Study coordinator: Pei Lim, BM, MSc, MD(Res), MRCP, FRCR
- Email: pei.lim@nhs.net
- Phone: 0044 (0)203 447 4437
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-stop MR-guided radiotherapy for urgent metastatic spinal cord compression
This study will test whether an MR linear accelerator can deliver urgent single-appointment radiotherapy for people with metastatic spinal cord compression so they do not need a separate planning CT.
-
Exploring genomic testing for cancer of unknown primary
This study is testing if genomic testing can help find the hidden source of cancer in patients with Cancer of Unknown Primary to improve treatment options and outcomes.
-
Investigating bowel bacteria changes in prostate cancer patients undergoing radiotherapy
This study is trying to see how the bacteria in the stool of prostate cancer patients change during and after pelvic radiotherapy and how these changes relate to their health and diet.
-
Combined Proton Therapy and Liver Transplant for Hilar Cholangiocarcinoma
This trial tests whether adding proton beam therapy plus chemotherapy and liver transplantation helps people with hilar cholangiocarcinoma.
-
Proton beam therapy for parotid cancer after surgery
This study tests whether proton beam therapy after surgery can reduce side effects and improve outcomes for adults with malignant parotid gland cancer.
-
Pre-surgery and pre-radiotherapy Tumour Treating Fields (Optune) for glioblastoma
This will test whether using Optune (Tumour Treating Fields) before surgery and again before radiotherapy is safe and workable for adults with a new glioblastoma diagnosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.